Vericel receives FDA approval for arthroscopic MACI delivery
Click Here to Manage Email Alerts
Key takeaways:
- Vericel announced FDA approval of its arthroscopically administered biologic cartilage repair product.
- MACI Arthro uses a minimally invasive approach to prepare the defect site and deliver the MACI implant.
Vericel has received FDA approval to expand its MACI label to include MACI Arthro, an arthroscopic delivery of MACI to repair symptomatic knee cartilage defects, according to a company press release.
According to the release, MACI Arthro provides surgeons with a minimally invasive approach to prepare the defect site and deliver the MACI implant, which involves autologous cultured chondrocytes on porcine collagen membrane.
“The approval of MACI Arthro represents another significant milestone in our strategy to provide innovative solutions for patients suffering from pain and dysfunction caused by cartilage defects in the knee,” Nick Colangelo, president and CEO of Vericel, said in the release. “MACI Arthro provides orthopedic surgeons and their patients with a less invasive option for MACI administration, which we believe has the potential to significantly increase penetration into the largest segment of the MACI addressable market and will support sustained top-tier revenue growth for the company in the years ahead.”
According to the release, MACI Arthro is the only arthroscopically administered restorative biologic cartilage repair product approved by the FDA.
In addition, Vericel announced that it will expand its target surgeon base to include those who perform a high volume of cartilage repair surgeries, according to the release.
Read more about
Click Here to Manage Email Alerts